Fortress Doses First Patients in Pivotal Gout Drug Trial
Crystalys Therapeutics has dosed the first patients in two global, randomized, double-blind Phase 3 trials of dotinurad, a once-daily...
New Clinical Sites Added for BriaCell’s Phase 3 Cancer Trial
Seventy-nine U.S. sites across 23 states are now open in BriaCell’s pivotal Phase 3 program in metastatic breast cancer,...
Clearmind’s New AUD Trial Completes First Cohort Enrollment
Clearmind Medicine has completed enrollment of the six-patient first cohort in its Phase I/IIa study of CMND-100, an oral...
Pfizer’s AI-Powered Feasibility and Cost Efficiency: The Future of Clinical Trial Recruitment
At the 2025 SCOPE Europe conference, industry leaders examined how artificial intelligence (AI) is reshaping feasibility assessment and patient...
Using Behavioral AI to Predict and Prevent Clinical Trial Dropouts
At SCOPE Europe 2025, we spoke with Dominique Demolle, CEO of Cognivia, about how behavioral AI is helping sponsors...
Eleva Advances C3G Drug CPV-104 into Phase 1b Trial
Eleva completed the single-ascending dose portion of its first-in-human study of CPV-104, a recombinant human Factor H, in 21...
Ogsiveo Trial Shows Long-Term Efficacy for Desmoid Tumors
Objective response on nirogacestat improved from 34.3% at year one to 45.7% with continuous treatment for up to four...
PIVOT-PO Data: A New Hope for Oral cUTI Antibiotic Needs
Non-inferiority was achieved in the pivotal Phase 3 PIVOT-PO trial of oral tebipenem HBr for complicated urinary tract infections,...
Neuphoria Updates Phase 3 Trial for Social Anxiety Drug
Neuphoria’s Phase 3 AFFIRM-1 study of BNC210 for the acute treatment of social anxiety disorder failed to demonstrate efficacy....
Adarx Presents Kidney Disease Data at ASN Kidney Week 2025
ADARx will present interim Phase 1 data for ADX-038, an siRNA targeting complement factor B, at ASN Kidney Week...